33 results
8-K
EX-2.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
(a)(ii) of the Seller Disclosure Schedule, together with the employer portion of all related FICA, state, local or foreign withholding, payroll, social … , slogans, trade dress and brands, domain names or online or other electronic identifiers, social media names, tags or handles, service names, or other
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
27 Oct 23
Regulation FD Disclosure
4:19pm
. Additionally, more than 30 drugs are currently in clinical development. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social
424B3
l5ctzo0n
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
94sf4rgjw62
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
1h797i gh9qhj
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
9gp5huz91pq3e 3gb
16 Jun 23
Business combination disclosure
8:08am
425
v237l5
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
msv25jxcepxv d9lnhe
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
424B5
i9sdvoc0
17 Nov 22
Prospectus supplement for primary offering
5:37pm